Phaseline

Targets › PLK1

PLK1 (Serine/threonine-protein kinase PLK1): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 2; Oncology; next expected readout Nov 2026.

Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome (APC/C) inhibitors, and the regulation of mitotic exit and cytokinesis. Polo-like kinase proteins act by binding and phosphorylating…. (UniProt, P53350)

Open in Phaseline: the race on PLK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cardiff OncologyOnvansertib
Serine/threonine-protein kinase PLK1 inhibitor
PLK1Phase 2Metastatic Colorectal Cancer; Small-cell Lung Cancer; Breast Cancer; Pancreatic CancerNov 2026
SillaJenBAL0891
Dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
TTK, PLK1Phase 1Advanced Solid TumorDec 2026
Nationwide Children's HospitalPTC596
Polo-like kinase 1 (PLK1) inhibitor
PLK1Phase 1High Grade GliomaMar 2029

Conditions

Metastatic Colorectal Cancer (1) Small-cell Lung Cancer (1) Breast Cancer (1) Pancreatic Cancer (1) Advanced Solid Tumor (1) High Grade Glioma (1)

Modalities

mixed (2), small molecule (1)

Companies

Cardiff Oncology (1) SillaJen (1) Nationwide Children's Hospital (1)

Related targets

TTK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.